The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Biocept's share price is $0.0001. Biocept's Book Value per Share for the quarter that ended in Jun. 2023 was $0.12. Hence, Biocept's PB Ratio of today is 0.00.
The historical rank and industry rank for Biocept's PB Ratio or its related term are showing as below:
During the past 12 years, Biocept's highest PB Ratio was 62.79. The lowest was 0.13. And the median was 2.37.
BIOCQ's PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.08 * Ranked among companies with meaningful PB Ratio only.
During the past 12 months, Biocept's average Book Value Per Share Growth Rate was -99.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -36.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -41.40% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Biocept was -30.30% per year. The lowest was -66.10% per year. And the median was -43.50% per year.
Back to Basics: PB Ratio
Biocept PB Ratio Historical Data
The historical data trend for Biocept's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biocept's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocept's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biocept's PB Ratio falls into.
Biocept PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Biocept's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Biocept PB Ratio Related Terms
Thank you for viewing the detailed overview of Biocept's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOCQ has been successfully added to your 